Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
Journal of Clinical Lipidology
BACKGROUND: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid ethyl ester approved at a dose of 4 g/day as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG $ 500 mg/dL). OBJECTIVE: In this prespecified exploratory analysis from the ANCHOR study of patients at high cardiovascular risk with TG $ 200 and ,500 mg/dL despite statin control of low-density lipoprotein cholesterol, we assessed the effects of IPE
... the effects of IPE on lipoprotein particle concentration and size and examined correlations of atherogenic particles with apolipoprotein B (ApoB). METHODS: Nuclear magnetic resonance spectroscopy was used to measure lipoprotein particle concentration and size. RESULTS: Compared with placebo (n 5 211), IPE 4 g/day (n 5 216) significantly reduced concentrations of: total (12.2%, P 5 .0002), large (46.4%, P , .0001), and medium (12.1%, P 5 .0068) very-low-density lipoprotein (VLDL) particles; total (7.7%, P 5 .0017) and small (13.5%, P , .0001) LDL particles; and total (7.4%, P , .0001) and large (31.0%, P , .0001) high-density lipoprotein particles. Atherogenic lipoprotein particles (total VLDL and total LDL) correlated with ApoB at baseline (R 2 5 0.57) and week 12 (R 2 5 0.65) as did total LDL particle concentration at baseline (R 2 5 0.53) and week 12 (R 2 5 0.59). Compared with placebo, IPE 4 g/day significantly reduced VLDL (7.7%, P , .0001) and high-density lipoprotein (1.2%, P 5 .0014) particle sizes with a modest but significant increase in LDL particle size (0.5%, P 5 .0031).